Palo Alto Investors’s Dianthus Therapeutics DNTH Stock Holding History

Palo Alto Investors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-27,019	Closed	-$610K	–	30
2022 Q3	$610K	Hold	27,019	–	–	0.05%	29
2022 Q2	$519K	Hold	27,019	–	–	0.05%	30
2022 Q1	$1.25M	Hold	27,019	–	–	0.1%	28
2021 Q4	$1.92M	Hold	27,019	–	–	0.12%	27
2021 Q3	$3.15M	Hold	27,019	–	–	0.19%	31
2021 Q2	$4.23M	Hold	27,019	–	–	0.23%	27
2021 Q1	$5.12M	Buy	27,019 +325	+1%	+$54.7K	0.29%	27
2020 Q4	$3.35M	Buy	26,694 +5,213	+24%	+$591K	0.18%	29
2020 Q3	$2.34M	Buy	21,481 +9,318	+77%	+$1.1M	0.13%	33
2020 Q2	$1.46M	Buy	+12,163	New	+$1.71M	0.09%	31

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Palo Alto Investors's DNTH Position: Q4 2022 in Review

Palo Alto Investors sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 27,019 shares — an estimated $610K sold.

Palo Alto Investors first reported a position in DNTH in Q2 2020 and held it in 10 quarters. The position peaked at $5.12M in Q1 2021. 54 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

Palo Alto Investors reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
Palo Alto Investors sold 27,019 Dianthus Therapeutics shares in Q4 2022, an estimated $610K.
Palo Alto Investors first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 10 quarters.
Palo Alto Investors's Dianthus Therapeutics position peaked at $5.12M in Q1 2021.
54 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Palo Alto Investors's 13F filing for Q4 2022, filed 14 Feb 2023.